Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
picaga-Met-hex-KuE
- Development stage
- Unknown
- Lead developer
- University of Wisconsin–Madison
- Modality
- Peptides
01
Overview
picaga-Met-hex-KuE: sourced facts only. name: "Biodistribution and metabolite analysis confirmed PSMA-targeting, minimal off-target uptake, and renal clearance for all picaga-Met-hex-KuE systems." [PMID:41359406]; target: "Biodistribution and metabolite analysis confirmed PSMA-targeting, minimal off-target uptake, and renal clearance for all picaga-Met-hex-KuE systems." [PMID:41359406]; developer: "Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, Wisconsin 53705, United States." [PMID:41359406]; modality: "mpatcn supported the formation of [18F][ScF], [44Sc][Sc], and [177Lu][Lu] complexes when conjugated to a PSMA-targeting peptide (picaga-Met-hex-KuE)." [PMID:41359406]
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on picaga-Met-hex-KuE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on picaga-Met-hex-KuE.